Overall, this study highlights PRPS activity as the molecular rheostat dictating the redox state in Myc-driven lymphomas and provides a proof-of-concept in how the tunability of a metabolic enzyme may be exploited for therapeutic benefit in Myc-driven lymphoma. This evidence concerns the gene MYC and lymphoma.